Document is current

Article History

Received: 25 September 2025

Accepted: 19 November 2025

First Online: 8 December 2025

Declarations

:

: All registry procedures complied with institutional and national ethics standards and the Declaration of Helsinki. Ethical approval was obtained from the respective Ethics Committees at all participating centers: Paris DRGI (CCTRIS MG/CP010.868), Berlin (EA1/048/10), Hamburg (MC-278/10), Regensburg (11–103-0181), Greifswald (BB113/10), Luebeck (11–135), Kiel (B328/11), Milan (Verbale Comitato Etico n.11), Rome ((A.199)/C.E/2011), Pavia (LEMS-01), Valencia (BIO-AMI-2010–01), Madrid (LEMS-01), Cottingham (R1697). Written informed consent was obtained from all participants. The LEMS registry protocol, patient information sheet, and informed consent form were reviewed and approved by the responsible ethics committees at participating centers in accordance with local regulations. All approvals were in place before site initiation and patient enrollment. Copies of approvals and study documents are on file with SERB SA (Brussels, Belgium).

: All authors have reviewed and approved the final manuscript for publication.

: HP and IH have no competing interests. AM received speaker’s speaker or consultancy honoraria or financial research support (paid to his institution) from Alexion AstraZeneca Rare Disease, Amgen, argenx, Axunio, Desitin, Genpharm, Grifols, Hormosan, Immunovant, Johneson & Johnson, Merck, Novartis, Octapharma, Regeneron, Sanofi and UCB. He serves as member (chairmen from 2019–2024) of the medical advisory board of the German Myasthenia Gravis Society. VP and CD are employees of Serb Pharmaceuticals.